Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:CDTX NASDAQ:DYN NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$38.27+5.3%$39.55$26.20▼$63.50$1.68B1.43562,832 shs644,589 shsCDTXCidara Therapeutics$66.37-1.7%$53.69$10.14▼$69.36$1.71B1.18425,951 shs558,355 shsDYNDyne Therapeutics$12.58+2.9%$10.23$6.36▼$46.81$1.74B1.083.08 million shs2.30 million shsSLDBSolid Biosciences$5.93+4.8%$5.74$2.41▼$10.07$440.74M2.441.16 million shs794,407 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+5.28%+2.63%-5.69%-3.06%-20.85%CDTXCidara Therapeutics-1.66%+1.78%+2.34%+173.35%+410.54%DYNDyne Therapeutics+2.95%+1.62%+34.12%+7.61%-73.26%SLDBSolid Biosciences+4.77%-2.95%-12.28%+111.03%-40.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics3.5019 of 5 stars4.43.00.00.01.34.20.0CDTXCidara Therapeutics3.5945 of 5 stars2.63.00.04.62.31.70.0DYNDyne Therapeutics3.1378 of 5 stars4.51.00.00.01.54.20.0SLDBSolid Biosciences3.4086 of 5 stars4.62.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.86Moderate Buy$99.00158.69% UpsideCDTXCidara Therapeutics 3.11Buy$64.14-3.36% DownsideDYNDyne Therapeutics 3.00Buy$33.80168.68% UpsideSLDBSolid Biosciences 3.17Buy$15.00152.95% UpsideCurrent Analyst Ratings BreakdownLatest SLDB, CDTX, DYN, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $14.008/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.008/8/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$59.00 ➝ $66.008/8/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $74.008/8/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $74.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $13.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$66.00 ➝ $36.00(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.43 per shareN/ACDTXCidara Therapeutics$1.27M1,325.31N/AN/A$19.76 per share3.36DYNDyne TherapeuticsN/AN/AN/AN/A$4.02 per shareN/ASLDBSolid Biosciences$8.09M57.08N/AN/A$3.32 per share1.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)CDTXCidara Therapeutics-$169.83M-$11.13N/AN/AN/AN/A-50.81%-42.46%11/6/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest SLDB, CDTX, DYN, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87-$1.65+$0.22-$1.65N/AN/A7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3616.36CDTXCidara TherapeuticsN/A16.4516.45DYNDyne Therapeutics0.1716.8316.83SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%CDTXCidara Therapeutics35.82%DYNDyne Therapeutics96.68%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%CDTXCidara Therapeutics3.89%DYNDyne Therapeutics14.14%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableCDTXCidara Therapeutics9025.36 million24.37 millionNo DataDYNDyne Therapeutics100142.26 million122.15 millionOptionableSLDBSolid Biosciences10077.87 million76.39 millionOptionableSLDB, CDTX, DYN, and APGE HeadlinesRecent News About These CompaniesMonashee Investment Management LLC Grows Position in Solid Biosciences Inc. $SLDB4 hours ago | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SLDB EarningsAugust 19, 2025 | marketbeat.comQ3 EPS Forecast for Solid Biosciences Increased by AnalystAugust 19, 2025 | americanbankingnews.comQ1 Earnings Forecast for SLDB Issued By Leerink PartnrsAugust 17, 2025 | marketbeat.comFY2025 EPS Estimate for Solid Biosciences Boosted by AnalystAugust 17, 2025 | marketbeat.comHC Wainwright Forecasts Lower Earnings for Solid BiosciencesAugust 17, 2025 | marketbeat.comQ3 Earnings Estimate for Solid Biosciences Issued By WedbushAugust 17, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Solid Biosciences (NASDAQ:SLDB) Price Target to $13.00August 17, 2025 | americanbankingnews.comLeerink Partnrs Weighs in on SLDB Q1 EarningsAugust 17, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street ZenAugust 17, 2025 | marketbeat.comSolid Biosciences' (SLDB) "Buy" Rating Reiterated at Chardan CapitalAugust 17, 2025 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for SLDBAugust 17, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Chardan CapitalAugust 16, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Price Target Lowered to $13.00 at JPMorgan Chase & Co.August 16, 2025 | marketbeat.comHC Wainwright Predicts Lower Earnings for Solid BiosciencesAugust 16, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Shares Up 9.9% Following Better-Than-Expected EarningsAugust 15, 2025 | marketbeat.comWedbush Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $14.00August 15, 2025 | marketbeat.com40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco LtdAugust 15, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading 9.9% Higher on Strong EarningsAugust 15, 2025 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.09 EPSAugust 14, 2025 | marketbeat.comSolid Biosciences Inc.: Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Buy the Dip? These Earnings Misses Offer Long-Term UpsideBy Nathan Reiff | August 7, 20254 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025Why Teradyne's 19% Rally Is Just Getting StartedBy Jeffrey Neal Johnson | August 3, 20253 Discounted Steel Stocks You Can DCA Into TodayBy Gabriel Osorio-Mazilli | July 26, 2025SLDB, CDTX, DYN, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$38.27 +1.92 (+5.28%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$37.25 -1.02 (-2.67%) As of 08/22/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Cidara Therapeutics NASDAQ:CDTX$66.37 -1.12 (-1.66%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$66.87 +0.50 (+0.75%) As of 08/22/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Dyne Therapeutics NASDAQ:DYN$12.58 +0.36 (+2.95%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$12.58 0.00 (0.00%) As of 08/22/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Solid Biosciences NASDAQ:SLDB$5.93 +0.27 (+4.77%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.90 -0.03 (-0.57%) As of 08/22/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access